155 related articles for article (PubMed ID: 34931090)
1. The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review.
Rezaei M; Barati S; Babamahmoodi A; Dastan F; Marjani M
Curr Ther Res Clin Exp; 2022; 96():100658. PubMed ID: 34931090
[TBL] [Abstract][Full Text] [Related]
2. Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review.
Kifle ZD
Metabol Open; 2021 Sep; 11():100116. PubMed ID: 34345815
[TBL] [Abstract][Full Text] [Related]
3. BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review.
Stack M; Sacco K; Castagnoli R; Livinski AA; Notarangelo LD; Lionakis MS
Clin Immunol; 2021 Sep; 230():108816. PubMed ID: 34352390
[TBL] [Abstract][Full Text] [Related]
4. Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic.
Weber MS; Nicholas JA; Yeaman MR
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34497100
[TBL] [Abstract][Full Text] [Related]
5. BTK inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Systematic Review.
Stack M; Sacco K; Castagnoli R; Livinski AA; Notarangelo LD; Lionakis MS
Res Sq; 2021 Mar; ():. PubMed ID: 33791689
[TBL] [Abstract][Full Text] [Related]
6. Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors.
Naik PP
J Transl Autoimmun; 2022; 5():100156. PubMed ID: 35493759
[TBL] [Abstract][Full Text] [Related]
7. Treating CLL with Bruton Tyrosine Kinase Inhibitors: The Role of the Outpatient Oncology Nurse.
Randhawa B; Lewis E; Owen C
Semin Oncol Nurs; 2021 Aug; 37(4):151177. PubMed ID: 34281733
[TBL] [Abstract][Full Text] [Related]
8. Platelet caspase-1 and Bruton tyrosine kinase activation in patients with COVID-19 is associated with disease severity and reversed in vitro by ibrutinib.
Claude L; Martino F; Hermand P; Chahim B; Roger PM; de Bourayne M; Garnier Y; Tressieres B; Colin Y; Le Van Kim C; Romana M; Baccini V
Res Pract Thromb Haemost; 2022 Nov; 6(8):e12811. PubMed ID: 36514346
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
10. Incubation Period of Severe Acute Respiratory Syndrome Novel Coronavirus 2 that Causes Coronavirus Disease 2019: A Systematic Review and Meta-Analysis.
Wassie GT; Azene AG; Bantie GM; Dessie G; Aragaw AM
Curr Ther Res Clin Exp; 2020; 93():100607. PubMed ID: 33071295
[TBL] [Abstract][Full Text] [Related]
11. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
Elife; 2020 Nov; 9():. PubMed ID: 33226337
[TBL] [Abstract][Full Text] [Related]
12.
Koshak DAE; Koshak PEA
Curr Ther Res Clin Exp; 2020; 93():100602. PubMed ID: 32863400
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
14. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
Palma M; Mulder TA; Österborg A
Front Immunol; 2021; 12():686768. PubMed ID: 34276674
[TBL] [Abstract][Full Text] [Related]
15. Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect.
Wang H; Guo H; Yang J; Liu Y; Liu X; Zhang Q; Zhou K
Exp Hematol Oncol; 2022 Sep; 11(1):60. PubMed ID: 36138486
[TBL] [Abstract][Full Text] [Related]
16. Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation.
Lougaris V; Baronio M; Vitali M; Tampella G; Cattalini M; Tassone L; Soresina A; Badolato R; Plebani A
J Allergy Clin Immunol; 2014 Jun; 133(6):1644-50.e4. PubMed ID: 24612681
[TBL] [Abstract][Full Text] [Related]
17. Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase.
Liu X; Pichulik T; Wolz OO; Dang TM; Stutz A; Dillen C; Delmiro Garcia M; Kraus H; Dickhöfer S; Daiber E; Münzenmayer L; Wahl S; Rieber N; Kümmerle-Deschner J; Yazdi A; Franz-Wachtel M; Macek B; Radsak M; Vogel S; Schulte B; Walz JS; Hartl D; Latz E; Stilgenbauer S; Grimbacher B; Miller L; Brunner C; Wolz C; Weber ANR
J Allergy Clin Immunol; 2017 Oct; 140(4):1054-1067.e10. PubMed ID: 28216434
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
Patel V; Balakrishnan K; Bibikova E; Ayres M; Keating MJ; Wierda WG; Gandhi V
Clin Cancer Res; 2017 Jul; 23(14):3734-3743. PubMed ID: 28034907
[No Abstract] [Full Text] [Related]
19. Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19.
Kumar R; Rathi H; Haq A; Wimalawansa SJ; Sharma A
Virus Res; 2021 Jan; 292():198235. PubMed ID: 33232783
[TBL] [Abstract][Full Text] [Related]
20. Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus.
Patsatsi A; Murrell DF
Front Med (Lausanne); 2021; 8():708071. PubMed ID: 34447768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
